Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Ethicon Endo-Surgery Picks Up Obesity Neurostim Patents From Cyberonics

This article was originally published in The Gray Sheet

Executive Summary

Johnson & Johnson subsidiary Ethicon Endo-Surgery expanded its obesity treatment portfolio Dec. 18, gaining exclusive rights to neurostimulation patents from Cyberonics

You may also be interested in...

Financings In Brief

Inverness raises funds for more acquisitions: Diagnostics firm will gross about $728 million from the sale of 11.8 million shares of its common stock at $61.49 each, expected to close Nov. 20, the firm announces Nov. 15. Proceeds are tabbed for working capital and "potential acquisitions or other investments, if and when suitable opportunities arise," the company says. Inverness Medical Innovations, which has inked more than a dozen acquisition deals so far this year, recently indicated that it plans to keep up the pace, with the goal of growing annual revenues to $3 billion by 2012 (1"The Gray Sheet" Nov. 5, 2007, p. 16). The Waltham, Mass.-based company notes that it also may use a portion of the anticipated proceeds from the stock offering to complete its pending $37 million acquisition of Australian diagnostics firm Panbio, which was announced Oct. 8 (2"The Gray Sheet" Oct. 15, 2007, In Brief). Underwriters for the stock offering include UBS Investment Bank, Jefferies & Company, Merrill Lynch, Leerink Swann, and Stifel, Nicolaus & Company. Inverness stock trades on the Amex exchange under the symbol "IMA.

Underpenetrated U.S. Gastric Banding Market Has Room For Two

With Johnson & Johnson expected to launch its Realize adjustable gastric band in the United States by the end of the year, what physicians and analysts consider a highly underpenetrated market will finally have some competition

Warning Letter Roundup & Recap – 31 March 2020

No device-related warning letters were released by the US FDA the week of 31 March.




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts